{"id":5954,"date":"2023-07-14T16:01:47","date_gmt":"2023-07-14T20:01:47","guid":{"rendered":"https:\/\/bridgebio.local\/news\/auto-draft\/"},"modified":"2023-07-14T13:28:10","modified_gmt":"2023-07-14T17:28:10","slug":"bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023","status":"publish","type":"post","link":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/","title":{"rendered":"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023"},"content":{"rendered":"<p align=\"left\"><strong>PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE)<\/strong> &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM clinical study in patients with transthyretin amyloid cardiomyopathy (ATTR-CM).<\/p>\n<p align=\"left\">To access the live webcast, please visit the \u201cEvents\u201d page within the Investors section of the BridgeBio website at\u00a0<a href=\"https:\/\/investor.bridgebiodev.wpengine.com\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>http:\/\/investor.bridgebiodev.wpengine.com<\/u><\/strong><\/a>. A replay of the webcast will be available on the BridgeBio website for 90 days following the event.<\/p>\n<p><strong>About BridgeBio Pharma, Inc.<\/strong><\/p>\n<p>BridgeBio Pharma (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit\u202f<a href=\"http:\/\/www.bridgebio.local\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>bridgebiodev.wpengine.com<\/u><\/strong><\/a>\u202fand follow us on\u202f<a href=\"https:\/\/www.linkedin.com\/company\/bridgebio\/\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>LinkedIn<\/u><\/strong><\/a>\u202fand\u202f<a href=\"https:\/\/twitter.com\/BridgeBioPharma\" target=\"_blank\" rel=\"nofollow noopener\"><strong><u>Twitter<\/u><\/strong><\/a>.<\/p>\n<p><strong>BridgeBio Contact:<\/strong><br \/>\nVikram Bali<br \/>\n<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fugVVwAx1GYYTInBeTohYDy4FLEcn5zgfziCScXYuDM_iXkWjOkg3QygLNq5Q7gd5LneNVpma5M7gKAxmAefYpFajTkwnRTdm371CnV3i-E=\" target=\"_blank\" rel=\"nofollow noopener\"><u>contact@bridgebiodev.wpengine.com<\/u><\/a><br \/>\n(650)-789-8220<\/p>\n","protected":false},"excerpt":{"rendered":"<p>PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[8],"tags":[],"class_list":["post-5954","post","type-post","status-publish","format-standard","hentry","category-news"],"acf":{"people":false,"external_link":"","presentation":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.4 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"BridgeBio\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-14T20:01:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-07-14T17:28:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Holly Condon\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:site\" content=\"@BridgeBioPharma\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Holly Condon\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/\",\"url\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/\",\"name\":\"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio\",\"isPartOf\":{\"@id\":\"https:\/\/bridgebio.com\/#website\"},\"datePublished\":\"2023-07-14T20:01:47+00:00\",\"dateModified\":\"2023-07-14T17:28:10+00:00\",\"author\":{\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\"},\"breadcrumb\":{\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bridgebio.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/bridgebio.com\/#website\",\"url\":\"https:\/\/bridgebio.com\/\",\"name\":\"BridgeBio\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/bridgebio.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca\",\"name\":\"Holly Condon\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/bridgebio.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g\",\"caption\":\"Holly Condon\"},\"url\":\"https:\/\/bridgebio.com\/author\/hcondon\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio","og_description":"PALO ALTO, Calif., July 14, 2023 (GLOBE NEWSWIRE) &#8212; BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of its management team will host an investor call on Monday, July 17 at 8:00 am ET to share topline results from the Phase 3 ATTRibute-CM [&hellip;]","og_url":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/","og_site_name":"BridgeBio","article_published_time":"2023-07-14T20:01:47+00:00","article_modified_time":"2023-07-14T17:28:10+00:00","og_image":[{"width":1200,"height":600,"url":"https:\/\/bridgebio.com\/wp-content\/uploads\/2019\/02\/BridgeBio_Share.png","type":"image\/png"}],"author":"Holly Condon","twitter_card":"summary_large_image","twitter_creator":"@BridgeBioPharma","twitter_site":"@BridgeBioPharma","twitter_misc":{"Written by":"Holly Condon","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/","url":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/","name":"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023 - BridgeBio","isPartOf":{"@id":"https:\/\/bridgebio.com\/#website"},"datePublished":"2023-07-14T20:01:47+00:00","dateModified":"2023-07-14T17:28:10+00:00","author":{"@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca"},"breadcrumb":{"@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bridgebio.com\/news\/bridgebio-to-host-investor-call-to-share-topline-30-month-results-from-the-phase-3-attribute-cm-study-in-patients-with-transthyretin-amyloid-cardiomyopathy-on-july-17-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bridgebio.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio to Host Investor Call to Share Topline 30-month Results from the Phase 3 ATTRibute-CM Study in Patients with Transthyretin Amyloid Cardiomyopathy on July 17, 2023"}]},{"@type":"WebSite","@id":"https:\/\/bridgebio.com\/#website","url":"https:\/\/bridgebio.com\/","name":"BridgeBio","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/bridgebio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/e56e9128cd840531b0acdca992cb1fca","name":"Holly Condon","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/bridgebio.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4465d7631588f41599cacc7a8380e613?s=96&d=mm&r=g","caption":"Holly Condon"},"url":"https:\/\/bridgebio.com\/author\/hcondon\/"}]}},"_links":{"self":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5954"}],"collection":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/comments?post=5954"}],"version-history":[{"count":0,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/posts\/5954\/revisions"}],"wp:attachment":[{"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/media?parent=5954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/categories?post=5954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bridgebio.com\/wp-json\/wp\/v2\/tags?post=5954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}